These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38436289)

  • 21. The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1-3 node positive breast cancer.
    Malam Y; Rabie M; Geropantas K; Alexander S; Pain S; Youssef M
    Cancer Rep (Hoboken); 2022 Aug; 5(8):e1546. PubMed ID: 34664429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria.
    Natsuhara KH; Losk K; King TA; Lin NU; Camuso K; Golshan M; Pochebit S; Brock JE; Bunnell CA; Freedman RA
    Oncologist; 2019 May; 24(5):595-602. PubMed ID: 30076279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
    Hannouf MB; Zaric GS; Blanchette P; Brezden-Masley C; Paulden M; McCabe C; Raphael J; Brackstone M
    Pharmacogenomics J; 2020 Feb; 20(1):27-46. PubMed ID: 31130722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncotype DX
    Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
    Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM; Klang SH; Ben-Baruch N; Geffen DB; Steiner M; Soussan-Gutman L; Merling S; Svedman C; Rizel S; Lieberman N
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.
    Holt S; Bertelli G; Humphreys I; Valentine W; Durrani S; Pudney D; Rolles M; Moe M; Khawaja S; Sharaiha Y; Brinkworth E; Whelan S; Jones S; Bennett H; Phillips CJ
    Br J Cancer; 2013 Jun; 108(11):2250-8. PubMed ID: 23695023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
    Fayaz S; Eissa HE; Demian GA
    J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score
    Berdunov V; Cuyun Carter G; Laws E; Luo R; Russell CA; Campbell S; Abdou Y; Force J
    Clinicoecon Outcomes Res; 2024; 16():471-482. PubMed ID: 38855430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J; Jacobson AF; Estabrook A; Smith SR; Boolbol SK; Feldman SM; Osborne MP; Boachie-Adjei K; Twardzik W; Tartter PI
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.
    McVeigh TP; Hughes LM; Miller N; Sheehan M; Keane M; Sweeney KJ; Kerin MJ
    Eur J Cancer; 2014 Nov; 50(16):2763-70. PubMed ID: 25240289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic Impact of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in France.
    Katz G; Romano O; Foa C; Vataire AL; Chantelard JV; Hervé R; Barletta H; Durieux A; Martin JP; Salmon R
    PLoS One; 2015; 10(6):e0128880. PubMed ID: 26086912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
    Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
    J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center.
    Thibodeau S; Voutsadakis IA
    Eur J Breast Health; 2019 Jul; 15(3):163-170. PubMed ID: 31312792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact and Cost-Effectiveness of Oncotype DX for Guiding Adjuvant Chemotherapy Decisions in Early Breast Cancer.
    El Karak F; Rassy E; Bassil J; Awali M; Hanna C; Saroufim A; Nasr F; Farhat F; Kattan J; Ghosn M; Paulden M
    Gulf J Oncolog; 2021 Jan; 1(35):27-35. PubMed ID: 33716210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.
    Chen C; Dhanda R; Tseng WY; Forsyth M; Patt DA
    J Oncol Pract; 2013 Jul; 9(4):182-7. PubMed ID: 23942918
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
    Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.